Biocon and Mylan nab FDA approval for Herceptin biosim
Co-developed by both companies, Ogivri will be used for the treatment of breast and gastric cancer patients.
Source: PharmaManufacturing.com - Category: Pharmaceuticals Source Type: news
More News: Cancer | Cancer & Oncology | Gastric (Stomach) Cancer | Gastroenterology | Herceptin | Pharmaceuticals